HK Stock Market Move | DUALITYBIO-B (09606) rose more than 5% during trading. The company's first ADC is expected to submit its IPO application within the year.

DUALITYBIO-B (09606) rose more than 5% in intraday trading, up 4.68% as of the time of writing, at 308.4 Hong Kong dollars, with a trading volume of 1.04 billion Hong Kong dollars. On the news front, according to the latest report "2025-2030 China Antibody Drug Conjugates (ADC) Industry Research and Market Investment Decision Report" released by China Research PricewaterhouseCoopers Industrial Research Institute, the Chinese ADC market is expected to exceed one hundred billion RMB in the next five years, becoming the world's second largest ADC market. It is reported that DUALITYBIO-B's DB-1419 (B7-H3/PD-L1 dual-target ADC) has shown excellent efficacy in solid tumor clinical trials, marking a technological breakthrough for Chinese companies in the field of dual-target ADC. According to the Zhongrun research report, according to Frost & Sullivan, the global ADC market is expected to reach approximately 10.4 billion US dollars by 2023 and is expected to reach 115.1 billion US dollars by 2032. According to DUALITYBIO-B's announcement, the company plans to submit an application for the listing of DB-1303 (HER2 ADC) for endometrial cancer in the United States and for breast cancer in China by 2025. The company's DB-1311 (B7-H3 ADC) has shown the best potential in prostate cancer, DB-1310 (HER3 ADC) is expected to catch up later; the combination of DB-1305 (TROP2 ADC) and dual-target exploration is leading globally, and the development of self-immune and dual-target ADCs is continuously promoting the exploration of the next generation of ADC frontiers.